黄芪注射液对中晚期非小细胞肺癌化疗后骨髓系统的影响

Influence of Huangqi injection on bone marrow in patients with mid and advanced stage nonsmall-cell lung cancer

目的：观察在非小细胞肺癌（NSCLC）患者化疗时应用黄芪注射液后近期疗效和骨髓造血变化。方法：将69例NSCLC患者分为治疗组35例,对照组34例。治疗组：化疗同时加黄芪注射液静脉滴注,每周5 d,连续5周;对照组：化疗5周。结果：治疗组与对照组白细胞下降程度的2～4级中,2级治疗组20.0%,对照组41.2%;3级治疗组11.4%,对照组23.5%;血红蛋白治疗组1＋2级28.6%,对照组58.8%;血小板治疗组1＋2级41.2%,对照组64.7%及白细胞治疗恢复时间,两组对比差异均具有统计学意义（P〈0.05）。结论：黄芪注射液与化疗合用可明显减轻NSCLC患者化疗后对骨髓系统的影响,值得临床推广应用。

Objective： To observe the last therapeutic effect of Hunmgqi injection in chemotherapy in patients with non-small call lung cancer（NSCLC） and the changes of bone marrow.Methods： All 69 patients were divided randomly into therapeutic group 35 cases,control 34 cases.Therapeutic group was chemotherapy combined with iv drip Huangqi injection on,5d/w,5 week,control group underwent chemotherapy only.Results： The decrease grade（Ⅱ～Ⅳ） of white blood cell was 20%（Ⅱ）,in therapeutic group compared with 41.2%（Ⅱ）;11.4%（Ⅲ）in therapeutic groap,23.5%（Ⅲ）in control group.Hemoglobin decrease grade（Ⅰ＋Ⅱ） was 28.6% in therapy group compared with 58.8% in control group.Platelet cell decrease grade（Ⅰ＋Ⅱ）was 41.2% compared with 64.7%,and the recovery time of white blood cell to normal all were showed significant difference between the two groups.Conclusion： Chemotherapy combined with Huang Qi injection could relieve toxicity of chemotherapy in patients with non-small cell lung cancer（NSCLC）.